Niranjan Kanesa-thasan - Feb 10, 2022 Form 4 Insider Report for Icosavax, Inc. (ICVX)

Role: Chief Medical Officer
Signature: /s/ Elizabeth Bekiroglu, Attorney-in-Fact for Niranjan Kanesa-Thasan
Stock symbol: ICVX
Transactions as of: Feb 10, 2022
Transactions value $: $0
Form type: 4
Date filed: 2/14/2022, 06:06 PM
Previous filing: Feb 4, 2022
Next filing: Feb 14, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ICVX	Common Stock	Award	$0	+19.5K	+8.73%	$0.00	243K	Feb 10, 2022	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ICVX	Stock Option	Award	$0	+82K		$0.00	82K	Feb 10, 2022	Common Stock	82K	$17.55	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units ("RSUs") which will vest as to 25% of the total number of RSUs granted on each of the first four anniversaries of February 10, 2022, subject to the reporting persons continued service through the applicable vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer and the RSUs have no expiration date.
F2	Includes 1,666 shares acquired under the Issuer's employee stock purchase plan on November 30, 2021.
F3	25% of the shares subject to the option will vest on February 10, 2023, and 1/48th of the shares subject to the option vest monthly thereafter, subject to the reporting person's continued service through the applicable vesting date.